Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A primary or metastatic malignant neoplasm affecting the bone or articular cartilage.
Biomarker and diagnostic research for bone cancer has been reported in the published literature.
61 clinical trials registered, 25 recruiting. Interventions under study include other interventions, procedural interventions, drug therapy, and medical devices. Pipeline includes 1 PHASE3, 4 PHASE2, 5 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07197645](https://clinicaltrials.gov/study/NCT07197645) |
Data assembled from 3 of 12 sources · Last updated Nov 3, 2026, 5:28 AM UTC
Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain |
PHASE1 |
Telix Pharmaceuticals (Innovations) Pty Limited |
RECRUITING |
[NCT05779670](https://clinicaltrials.gov/study/NCT05779670) | Adherence to a Personalized Home Exercise Program in Patients With Bone Tumor Undergoing Lower Extremity Salvage Surgery | — | Istituto Ortopedico Rizzoli | RECRUITING |
[NCT07325578](https://clinicaltrials.gov/study/NCT07325578) | U.S. Prospective Evaluation of EPIONE Device for Percutaneous MSK Procedures | NA | Precision IO Group | RECRUITING |
[NCT06720142](https://clinicaltrials.gov/study/NCT06720142) | Mg OSTEOCRETE Post-Treatment Outcomes | — | Santiago Lozano-Calderon | RECRUITING |
[NCT03442465](https://clinicaltrials.gov/study/NCT03442465) | Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas | — | Memorial Sloan Kettering Cancer Center | RECRUITING |
431 publications have been identified in PubMed for bone cancer. Kisho has analyzed 209 by research type. Research spans Basic Science / Preclinical (45%), Review / Meta-Analysis (24%), and Gene Therapy / Novel Therapeutics (13%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 95 | 45% |
Research summaries | 50 | 24% |
New treatment approaches | 28 | 13% |
Disease patterns and progression | 21 | 10% |
Testing and diagnosis research | 9 | 4% |
Clinical study results | 5 | 2% |
Patient case studies | 1 | 0% |
Jiang X (2026). [PMID: 42087052](https://pubmed.ncbi.nlm.nih.gov/42087052/). *Phytother Res*. [Basic Science / Preclinical]
Arfaoui J (2026). [PMID: 41611648](https://pubmed.ncbi.nlm.nih.gov/41611648/). *ACS Biomater Sci Eng*. [Review / Meta-Analysis]
Hang LH (2026). [PMID: 41999973](https://pubmed.ncbi.nlm.nih.gov/41999973/). *Neuropharmacology*. [Basic Science / Preclinical]
Pang J (2026). [PMID: 42140592](https://pubmed.ncbi.nlm.nih.gov/42140592/). *Brain Res Bull*. [Basic Science / Preclinical]
Bagnato G (2026). [PMID: 41847386](https://pubmed.ncbi.nlm.nih.gov/41847386/). *Front Cell Dev Biol*. [Review / Meta-Analysis]
Cheng X (2026). [PMID: 41898354](https://pubmed.ncbi.nlm.nih.gov/41898354/). *Biomedicines*. [Review / Meta-Analysis]
Xu C (2026). [PMID: 41601212](https://pubmed.ncbi.nlm.nih.gov/41601212/). *Phytother Res*. [Basic Science / Preclinical]
Jayarangaiah A (2026). [PMID: 29939688](https://pubmed.ncbi.nlm.nih.gov/29939688/). *Unknown Journal*. [Epidemiology / Natural History]
Hassan NMH (2026). [PMID: 41776189](https://pubmed.ncbi.nlm.nih.gov/41776189/). *Sci Rep*. [Gene Therapy / Novel Therapeutics]
Wei L (2026). [PMID: 41869665](https://pubmed.ncbi.nlm.nih.gov/41869665/). *Front Oncol*. [Epidemiology / Natural History]